Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J DeAngelo

Showing results (121-130 of 320) with videos related to

Pageof 32
Sort By:
Blood|October 2, 2004
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.
Cancer|March 29, 2019
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Blood Cancer Journal|August 10, 2020
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenDaniel J DeAngelo, Anjali S Advani, David I Marks, et al.
American Journal of Hematology|May 7, 2016
Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remissionOfir Wolach, Kristen E Stevenson, Martha Wadleigh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2022
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for InterventionAndrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemiaGary J Schiller, Susan M O'Brien, Arnaud Pigneux, et al.
Journal of the National Cancer Institute|March 22, 2024
Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemiaAndrew Hantel, Andrew M Brunner, Jesse J Plascak, et al.
Leukemia Research|June 19, 2013
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)Eyal C Attar, Philip C Amrein, James W Fraser, et al.
The New England Journal of Medicine|June 14, 2016
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Blood|September 20, 2021
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemiaDaniel J DeAngelo, Brian A Jonas, Jane L Liesveld, et al.
Pageof 32

Showing results (121-130 of 320) with videos related to

Sort By:
Pageof 32
Blood|October 2, 2004
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.
Cancer|March 29, 2019
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Blood Cancer Journal|August 10, 2020
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenDaniel J DeAngelo, Anjali S Advani, David I Marks, et al.
American Journal of Hematology|May 7, 2016
Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remissionOfir Wolach, Kristen E Stevenson, Martha Wadleigh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2022
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for InterventionAndrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemiaGary J Schiller, Susan M O'Brien, Arnaud Pigneux, et al.
Journal of the National Cancer Institute|March 22, 2024
Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemiaAndrew Hantel, Andrew M Brunner, Jesse J Plascak, et al.
Leukemia Research|June 19, 2013
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)Eyal C Attar, Philip C Amrein, James W Fraser, et al.
The New England Journal of Medicine|June 14, 2016
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Blood|September 20, 2021
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemiaDaniel J DeAngelo, Brian A Jonas, Jane L Liesveld, et al.
Pageof 32